Literature DB >> 15180335

Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes.

Kiyomi Ito1, J Brian Houston.   

Abstract

PURPOSE: To compare three liver models (well-stirred, parallel tube, and dispersion) for the prediction of in vivo intrinsic clearance (CL(int)), hepatic clearance (CLh). and hepatic availability (Fh) of a wide range of drugs in the rat using in vitro data from two in vitro sources.
METHODS: In vitro CL(int) was obtained from studies using isolated rat hepatocytes (35 drugs) or rat liver microsomes (52 drugs) and used to predict in vivo CL(int) using reported scaling factors, and subsequently CLh and Fh were predicted based on the three liver models. In addition, in vivo CL(int) values were calculated from the reported values of CLh based on each of the three models.
RESULTS: For all of the parameters, predictions from hepatocyte data were consistently more accurate than those from microsomal data. Comparison of in vitro and in vivo CL(int) values demonstrated that the dispersion model and the parallel tube model were comparable and more accurate (less bias, more precise) than the well-stirred model. For CLh and Fh prediction, the three models performed similarly.
CONCLUSIONS: Considering the statistics of the predictions for three liver models, the use of parallel tube model is recommended for the evaluation of in vitro CL(int) values both from microsomes and hepatocytes. However, for the prediction of the in vivo drug (hepatic) clearance from in vitro data, as there are minimal differences between the models, the use of the well-stirred liver model is recommended.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15180335     DOI: 10.1023/b:pham.0000026429.12114.7d

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  23 in total

1.  Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes.

Authors:  R S Obach
Journal:  Drug Metab Dispos       Date:  1999-11       Impact factor: 3.922

Review 2.  Role of pharmacokinetics and metabolism in drug discovery and development.

Authors:  J H Lin; A Y Lu
Journal:  Pharmacol Rev       Date:  1997-12       Impact factor: 25.468

3.  Regional drug delivery II: relationship between drug targeting index and pharmacokinetic parameters for three non-steroidal anti-inflammatory drugs using the rat air pouch model of inflammation.

Authors:  A J Stevens; S W Martin; B S Brennan; A McLachlan; L A Gifford; M Rowland; J B Houston
Journal:  Pharm Res       Date:  1995-12       Impact factor: 4.200

Review 4.  Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance.

Authors:  J B Houston
Journal:  Biochem Pharmacol       Date:  1994-04-29       Impact factor: 5.858

5.  Sigmoidal kinetics of CYP3A substrates: an approach for scaling dextromethorphan metabolism in hepatic microsomes and isolated hepatocytes to predict in vivo clearance in rat.

Authors:  L E Witherow; J B Houston
Journal:  J Pharmacol Exp Ther       Date:  1999-07       Impact factor: 4.030

6.  Complications in the estimation of hepatic blood flow in vivo by pharmacokinetic parameters. The area under the curve after the concomitant intravenous and intraperitoneal (or intraportal) administration of acetaminophen in the rat.

Authors:  K S Pang; J R Gillette
Journal:  Drug Metab Dispos       Date:  1978 Sep-Oct       Impact factor: 3.922

7.  Kinetics of drug metabolism in rat liver slices: IV. Comparison of ethoxycoumarin clearance by liver slices, isolated hepatocytes, and hepatic microsomes from rats pretreated with known modifiers of cytochrome P-450 activity.

Authors:  D J Carlile; N Hakooz; J B Houston
Journal:  Drug Metab Dispos       Date:  1999-04       Impact factor: 3.922

8.  Scaling factors to relate drug metabolic clearance in hepatic microsomes, isolated hepatocytes, and the intact liver: studies with induced livers involving diazepam.

Authors:  D J Carlile; K Zomorodi; J B Houston
Journal:  Drug Metab Dispos       Date:  1997-08       Impact factor: 3.922

9.  Induction of propranolol metabolism by the azo dye sudan III in rats.

Authors:  R Ishida; S Obara; Y Masubuchi; S Narimatsu; S Fujita; T Suzuki
Journal:  Biochem Pharmacol       Date:  1992-06-09       Impact factor: 5.858

10.  Determination of hepatic blood flow in the rat using sequential infusions of indocyanine green or galactose.

Authors:  G M Pollack; K L Brouwer; K B Demby; J A Jones
Journal:  Drug Metab Dispos       Date:  1990 Mar-Apr       Impact factor: 3.922

View more
  41 in total

Review 1.  Applications of human pharmacokinetic prediction in first-in-human dose estimation.

Authors:  Peng Zou; Yanke Yu; Nan Zheng; Yongsheng Yang; Hayley J Paholak; Lawrence X Yu; Duxin Sun
Journal:  AAPS J       Date:  2012-03-10       Impact factor: 4.009

2.  Prediction of human metabolic clearance from in vitro systems: retrospective analysis and prospective view.

Authors:  David Hallifax; Joanne A Foster; J Brian Houston
Journal:  Pharm Res       Date:  2010-07-27       Impact factor: 4.200

3.  A semiphysiologically based pharmacokinetic modeling approach to predict the dose-exposure relationship of an antiparasitic prodrug/active metabolite pair.

Authors:  Grace Zhixia Yan; Claudia N Generaux; Miyoung Yoon; Rachel B Goldsmith; Richard R Tidwell; James E Hall; Carol A Olson; Harvey J Clewell; Kim L R Brouwer; Mary F Paine
Journal:  Drug Metab Dispos       Date:  2011-09-27       Impact factor: 3.922

4.  A novel strategy for physiologically based predictions of human pharmacokinetics.

Authors:  Hannah M Jones; Neil Parrott; Karin Jorga; Thierry Lavé
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

5.  Predictions of the in vivo clearance of drugs from rate of loss using human liver microsomes for phase I and phase II biotransformations.

Authors:  Michael A Mohutsky; Jenny Y Chien; Barbara J Ring; Steven A Wrighton
Journal:  Pharm Res       Date:  2006-03-24       Impact factor: 4.200

Review 6.  Prediction of hepatic clearance in human from in vitro data for successful drug development.

Authors:  Masato Chiba; Yasuyuki Ishii; Yuichi Sugiyama
Journal:  AAPS J       Date:  2009-04-30       Impact factor: 4.009

7.  Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data.

Authors:  Agnès Poirier; Anne-Christine Cascais; Christoph Funk; Thierry Lavé
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-11-20       Impact factor: 2.745

8.  Toxicokinetic Triage for Environmental Chemicals.

Authors:  John F Wambaugh; Barbara A Wetmore; Robert Pearce; Cory Strope; Rocky Goldsmith; James P Sluka; Alexander Sedykh; Alex Tropsha; Sieto Bosgra; Imran Shah; Richard Judson; Russell S Thomas; R Woodrow Setzer
Journal:  Toxicol Sci       Date:  2015-06-16       Impact factor: 4.849

9.  Lucidone suppresses hepatitis C virus replication by Nrf2-mediated heme oxygenase-1 induction.

Authors:  Wei-Chun Chen; Sheng-Yang Wang; Chien-Chih Chiu; Chin-Kai Tseng; Chun-Kuang Lin; Hui-Chun Wang; Jin-Ching Lee
Journal:  Antimicrob Agents Chemother       Date:  2012-12-17       Impact factor: 5.191

10.  Simulating microdosimetry in a virtual hepatic lobule.

Authors:  John Wambaugh; Imran Shah
Journal:  PLoS Comput Biol       Date:  2010-04-22       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.